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ABSTRACT
Objective To identify any improvements in pain or
function in patients with chronic plantar
fasciitis following the use of a tension night splint
(TNS).
Methods Single-blinded randomised controlled trial,
with participants split evenly between intervention
group (TNS + home exercise programme/HEP) and
control group (HEP only). Follow-up at 3 months, with
interim data at 6 weeks.
Results 40 patients recruited. Mean age 52.1 years,
33% male, mean body mass index 30.8 kg/m2, mean
duration of symptoms of 25 months. Improvement in
self-reported ‘average pain’ in the intervention group
from 6.8/10 at baseline to 5.6/10 at 6 weeks, and
5.3/10 at 3 months (both clinically and statistically
significant at both time points), compared with control
group of 7.1/10 at baseline to 6.2/10 at 6 weeks and
5.6/10 at 3 months (significant only at 3 months).
Improvements in self-reported ‘worst pain’, ‘pain
walking’ and ‘pain first thing in the morning’ in both
groups at all time periods. Improvements were seen in
revised Foot Function Index at all time points in both
groups, but limited changes seen in flexibility and no
significant changes in anxiety or depression Hospital
Anxiety and Depression Scale domains or
sleep quality in either group. However, no
differences were seen between the
outcomes seen in the two
groups for the majority of the measures studied.
Conclusions Improvements in pain and some
functional measures seen in both groups, with few, if
any, differences seen in outcomes between the
intervention group compared with the control group.
However, ongoing pain symptoms were reported in
both groups, suggesting that ‘help’ rather than ‘cure’
was obtained for the majority. There is a possibility of
earlier benefit seen in the intervention group compared
with the control group, but data are unclear and further
work may be needed.
Trial registration number ClinicalTrials.gov:
NCT02546115; results.
BACKGROUND
Plantar fasciitis is a common condition
causing under-surface heel pain. This most
typically affects people age 40–60, is more
common in women than men and can affect
both sedentary and active populations.1–3
Histological findings are typically that of
myxoid degeneration, rather than inflam-
matory processes, and plantar fasciitis is
What are the new finding?
" There is limited and inconsistent evidence for the
use of tension night splints previously published,
particularly in a population with chronic plantar
fasciitis. This structured single-blinded study
shows some benefits in pain and local function,
albeit not in flexibility, in both of the groups
studied, with a possibility of earlier benefit seen
in the intervention group. The very limited differ-
ences in outcome seen between the groups
questions the clinical effectiveness in outcomes
in this population of the use of a tension night
splint.
" Patients with even very chronic symptoms of
plantar fasciitis have a significant improvement in
various pain markers with a structured home
exercise programme; however, it is not clear if
the addition of a tension night splint device has
much, if any, additional benefit beyond this.
" Assessment of flexibility seems to improve less
than the reduction in pain suggests, indicating
that benefits are seen directly, rather than just by
improvements in soft-tissue flexibility.
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akin to an ‘over-use’ or ‘under-recovery’ type of condi-
tion, rather than a single acute injury.3–5 Due to the
lack of an inflammatory-driven process, this condition
is sometimes referred to as ‘plantar fasciosis’ or
‘plantar fasciopathy’ in some published works, but for
the purposes of this study the name ‘plantar fasciitis’
will continue to be used as this remains its the most
common form; however, the limitations of this term
are recognised.
The plantar fascia itself is a tough band of connective
tissue in the sole of the foot. It originates at the medial
process of the tuberosity of the calcaneus and inserts in
slips to the proximal phalanxes. It has a role in
supporting the longitudinal arch of the foot, but also
has roles in proprioception and peripheral motor coor-
dination and contains Pacini and Ruffini corpuscles
and nerve endings.6 Originating as it does from the
under-surface of the calcaneus, the plantar fascia is
sometimes viewed as the functional end point of the
Achilles tendon, which is attached to the posterior
margin of the calcaneus, and there are superficial
fibres directly connecting the two structures which
persist into adult life.7 Increasing tension in the
Achilles tendon increases strain within the plantar
fascia which may be a contributing factor to the devel-
opment of plantar fasciitis although the evidence
remains unclear.8 9 Tight posterior chain muscles
(hamstrings, gastrocnemius, soleus) are often found in
patients with plantar fasciitis,10 11 with a reduction in
ankle dorsiflexion being one of the most significant
risk factors for the development of plantar fasciitis.12
Addressing any particular tightness in the calf muscle
is therefore a key consideration in the management of
patients with plantar fasciitis, with improvements in
tightness correlating well to improvements in pain in
these patients.13
Most patients with plantar fasciitis will improve
within 12 months, but at least 10% may go on to
develop persisting symptoms.2 14 15 There is evidence
of benefit from treatment with various low-risk conser-
vative therapies including rest/activity modification,
stretches and/or taping,13 15–17 insoles/orthotics18 and
possibly some evidence for the use of tension night
splints (TNS) although this remains uncertain.19–26
Corticosteroid and local anaesthetic injections are
often used in patients with plantar fasciitis, and a
variety of differing techniques and broad outcome
figures for success rates are reported in the litera-
ture; however, some papers report a plantar fascia
rupture rate of up to 10% indicating that some
caution may be needed.27–30 If these measures prove
unsuccessful, then a range of more invasive options
have been suggested including extracorporeal shock-
wave therapy,31 32autologous blood injections33–35 or
surgery.36–38 However, comparing outcomes from
these different options is often difficult due to the
heterogeneity of patient populations, treatment inter-
ventions and follow-up, and many of these have not
been subject to rigorously designed investigation.
Many different validated measures exist both for
specific foot pain and wider function. Specific foot
measures include forms of the Foot Function Index/
Revised Foot Function Index (FFI/FFI-R), which is a
self-rating questionnaire with good test–retest reli-
ability, which has moderate-to-high levels of
correlation with the 36-Item Short Form Health Survey
(SF-36).39–41 The 16-item Manchester-Oxford Foot
Questionnaire (MOXFQ) has been validated against
both the SF-36 and the American Orthopaedic Foot
and Ankle Score (AOFAS) questions for a wide range
of foot and ankle problems,42–44 with further work
showing validity from a combined, single score rather
than the original subscales.45 The Foot and Ankle
Ability Measure (FAAM) questionnaire has also been
found to be valid, with high correlation with the SF-36
physical function subscale.46 Wider aspects of function
which are important to consider include global health
function which can be assessed by the EuroQol five
dimensions questionnaire (EQ-5D) which has good
validity across a number of populations and the ‘5L’
version reduces the ceiling effect seen in previous
versions of the questionnaire.47 For simplicity, the
global self-reported percentage health score is included
in this study to give an overall indication of health,
with a higher score indicating better self-rated overall
health. Other considerations include the possibility of
the presence of neuropathic pain, sleep disturbance
and mental health functioning, which may all influence
and be influenced by overall pain levels. The Hospital
Anxiety Depression Scale (HADS), which has been vali-
dated across a range of populations, gives 0–21
subscales for anxiety and depression symptoms, with a
higher score indicating more symptoms.48 49 Sleep
disturbance is another issue which is common in
patients with pain from a range of sources, and anec-
dotally patients often report that the TNS device can
adversely affect sleep quality. To measure sleep quality,
the Pittsburgh Sleep Quality Index (PSQI) was used in
this study. This gives a measure of sleep quality across
a range of subscales, and for simplicity the total score
How might it impact on clinical practice in the near
future?
This raises questions of the effectiveness of off-the-shelf tension
night splint devices in patients with chronic plantar fascia pain.
Patient benefit was seen in both groups, and limited, if any differ-
ences seen between groups. However, these data do strengthen
the evidence for discussion with patients about expected benefits
from either/both treatments in those with very chronic symptoms
and suggest that some benefits in pain are possible with rela-
tively simple interventions.
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is included here across a 0–21 scale, with higher value
indicating poorer sleep quality.50 51
The painDETECT questionnaire was originally devel-
oped for the assessment of patients with chronic low
back pain and has high sensitivity, specificity and posi-
tive predictive value for the presence of neuropathic
pain in a prospective multicentre trial.52 Following this
the questionnaire has been used in a wide range of
settings with differing clinical problems,53 54 and there
are thoughts that some patients with chronic tendinop-
athy may also score positively for neuropathic pain
using painDETECT, the significance of which remains
unclear currently.55 Scoring 19–38 suggests a 90% like-
lihood of a neuropathic pain component to a patient’s
symptoms, with 13–18/38 being an ambiguous result
and 0–12/38 suggests that neuropathic pain component
is unlikely (<15%). Identification of those patients with
a previously unknown neuropathic pain component
may allow alternative treatments, or treatments along-
side that for the nociceptive component of pain.
The use of a TNS device to assist in the stretching of
the calf muscle complex has a plausible rationale for
use and benefit in the treatment of patients with
chronic plantar fasciitis. However, there is limited
published evidence of benefit to date of this interven-
tion, despite it being in routine clinical use. A small
case series, published in 1991, suggested benefit from
the use of night splints in patients with recalcitrant
plantar fasciitis.19 Following this, a small prospective
randomised control trial (RCT published in 1996
showed improved outcomes in a group treated with
night splint alongside other treatments which included
stretching, Non-Steroidal Anti-Inflammatory
Drugs (NSAIDs) and a heel cup, compared with a
group without a splint, using clinical outcome meas-
ures.20 However, a larger prospective RCT published
in 1999 showed no difference in outcomes of treatment
with the addition of a TNS with clinical outcome and
SF-36 used as outcome measures.21 A different cross-
over study published in 1998 and which used the
AOFAS ankle–hindfoot rating and the Mayo Clinical
Scoring System demonstrated improvements with the
addition of the splint devices.22 One large study in
2001 compared two different orthotic devices and a
TNS device, and found overall no differences between
the groups in terms of outcome, but a higher discontin-
uation rate in the TNS group.23 A retrospective study
sought to compare the outcomes from simple stretch-
based programme and those from the use of a TNS,
and this found quicker recovery time and fewer further
treatments were required in the TNS group, although
the retrospective nature of this study and the lack of
randomisation means that these results are subject to
greater bias than other studies.24 A small case series of
12 patients using a specific TNS device was published
in 2002 suggesting good results with both pain and a
functional scale and high levels of tolerability form this
device, but the small study size and lack of control or
comparison group limits the impact of this research.25
Lastly, a retrospective study based in the same depart-
ment as this study found that patients reported good
improvements in pain following the use of a TNS, but
that 30% has ceased wearing the splint within 1month
from a variety of factors. However, the retrospective
nature of this study and the lack of a control group
again makes reliable assessment from this study diffi-
cult.26 A systematic review published in 2015, but using
a search from November 2013, demonstrated that
overall there was uncertain evidence for the use of
TNS devices to treat patients with plantar fasciitis.56
Given this uncertainty, this study seeks to investigate
the outcomes of a modern commercially available night
splint in patients with chronic plantar fasciitis in a
rigorous manner, using broad and reliable outcome
measures of pain and function, to better determine its
use in this condition in routine use.
METHODS
Patients who were being treated by the author in their
clinic for symptoms of plantar fasciitis, and who had
not benefited from a home exercise programme (HEP)
already, were assessed for suitability to enter the study
and if the inclusion/exclusion criteria were met. Base-
line data were recorded by the author including
baseline patient-rated outcome measures (PROMs) and
measures of baseline flexibility, both of which are
detailed below. Participants were then reviewed by the
study nurse practitioner who advised them about their
group allocation, and taught the participants in the
intervention group how to apply the TNS device.
Participants were then followed up at 6 weeks and
3months by the study author, and repeat measure-
ments were taken at each appointment. The author
remained blind to treatment allocation until after the
participants completed the 3-month follow-up assess-
ment, and no accidental unblinding occurred during
the study.
Inclusion/exclusion criteria
Patients were required be over the age of 18, to have
had unilateral plantar fasciitis symptoms only for at
least 4months, with pain reproduced on palpation on
the medial calcaneal tubercle at the plantar fascia
attachment, and with pain on loading, and have the
diagnosis confirmed on either ultrasound (plantar
fascia thickening of >4mm, without full/partial thick-
ness tear) or MRI.57 Exclusion criteria included
previous or current partial or full thickness tears of the
Achilles or plantar fascia (to avoid risk of further
injury), lower limb sensorimotor or vascular problems
(as these could be adversely affected by the use of the
splint), those with other causes for their pain (such as
referred pain, or inflammatory/connective tissue disor-
ders) or those that could not adequately apply the
splint device. Suitable patients who met the criteria
had the study discussed with them, were given written
Wheeler PC. BMJ Open Sport Exerc Med 2017;3:e000234. doi:10.1136/bmjsem-2017-000234 3
Open Access
group.bmj.com on July 10, 2017 - Published by http://bmjopensem.bmj.com/Downloaded from 
information about the study and if they wished to
participate were booked in to commence formal
enrolment.
Consent and randomisation
Participants were consented to enter the study and
randomised by a study nurse practitioner
who remained independent from the rest of the
study. Participants were allocated equally to either
group A (the ‘intervention group’, who received a
HEP and TNS) or group B (the ‘control group’,
who received a HEP only) using the ‘Sealed Enve-
lope’ software (www.sealedenvelope.com, Sealed
Envelope)
Intervention
Both groups were given a structured HEP which
included static stretches of the plantar fascia, the calf
(selectively involving both gastrocnemius and soleus for
different stretches), plus Flexor Hallucis Longus (FHL)
and hamstrings, as well as calf and intrinsic foot muscle
strengthening and balance training exercises. All
participants were taught how to perform and progress
their HEP themselves based on their progress at base-
line. Their technique was checked at the interim
(6week) appointment and any necessary corrections
made. All patients were also given written material to
support the use of this HEP.
In addition to the HEP, participants who were rando-
mised to group A (intervention group) were also given
a commercially available TNS device (LA Brace Plantar
Fasciitis Night Splint) which was bought from a
medical supply company before the study commenced.
Patients were taught how to apply the device by the
study nurse practitioner, and had her contact details
should any further assistance about the device be
required. They were instructed how to alter the tension
within the splint device over time both for comfort and
to maintain a dorsiflexion force during the interven-
tion period. Figure 1 is a picture of the TNS device
used in this study.
Data collection
Patients completed a structured questionnaire about
their symptoms before treatment commenced and at
each the 6week and 3-month follow-up visits. These
outcome measures include questions about pain, as
well as a range of validated PROMs which include
questionnaires about local function (FFI-r and
MOXFQ, in addition to measures of global function
(EQ-5D-5L). Questionnaires are also used to
examine the impact of symptoms of other areas of
functioning including measures of anxiety and
depression symptoms (HADS) and sleep quality
(PSQI). In addition, questionnaires are used to quan-
tify levels of physical activity. These include the
short-form (7-day recall) version of the International
Physical Activity Questionnaire, and two ‘vital signs’
physical activity questions.
In addition, physical assessments of flexibility were
taken by the lead investigator using a hand-held goni-
ometer (the range of passive ankle dorsiflexion with
the subject in a prone position with the knee both
extended and flexed to 90!, and an assessment of
popliteal angle with the subject lying supine, with the
hip flexed to 90!, and an assessment of the range of
knee extension with 180! being fully extended). The
‘knee-to-wall’ distance was recorded as a measure of
flexibility in a more functional position, measuring the
distance in millimetres a subject could move their foot
back from the wall and still just touch the knee to the
wall without the heel lifting. In addition, an assessment
of plantar fascia thickness was recorded using a muscu-
loskeletal ultrasound (GE LogiqE) with an average of
three recordings made to reduce intraobserver error
between measures, with previous work showing a
reduction in plantar fascia thickness correlated to
improvement in symptoms.58
The primary outcome measure studied was a change in
average pain (as recorded on a 0–10 scale) between base-
line and at 3months, with the remainder of the outcome
measures studied being secondary measures to this.
Those participants who were in the control group and
Figure 1 Tension night splint device.
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who had not improved significantly at 3months were
offered a TNS after the final study follow-up.
Ethical permissions
This study has all necessary permissions and is registered
on a publicly accessible database (ClinicalTrials.Gov
identifier NCT02546115). The study was given a favour-
able opinion from an NHS Research Ethics Committee
(REC ref 14/WS/1069) and has local site approvals.
Statistical analysis
An a priori power calculation was performed using
available data for improvements in self-reported pain.
This indicated that a range of between 15 and 25
participants in total were needed based on previously
published pre/post differences. Allowing for possible
drop-outs permissions were granted to recruit a total of
40 participants, split evenly between the intervention
and control groups.
Data were recorded prospectively at baseline, and on
an ongoing basis at clinic follow-up. This was collated
into an Excel spreadsheet (MS Excel from MS Office
2011, V. 14.5.7) and analysed in SPSS (IBM SPSS
Statistics, V. 23).
Comparisons were made between the baseline data
and data from the 6week, and the 3-month follow-up
appointments, with most of the outcome measures in
this dataset being scale data. The Shapiro-Wilk test was
used to assess normality as the sample sizes were small.
As most the data were found to be normally distrib-
uted, the analysis was predominantly performed with
parametric testing, typically paired-samples t-test for
comparison within groups, and independent-samples t-
test for comparison between groups. Statistical signifi-
cance was set at p<0.05. All data were analysed on an
intention-to-treat basis, deliberating not accounting for
the amount of time patents wore the device, mimicking
the effect in the real world.
RESULTS
A total of 41 participants with chronic plantar fasciitis
treated by the author in their hospital clinic were
initially identified as being potentially suitable for
inclusion. One patient was initially put forward to enter
Figure 2 CONSORT flowchart.
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the study, but after baseline assessment chose not to
continue the study, leaving a total of 40 patients
recruited. All patients completed the study with final
data at 3months; however, two patients did not attend
for the interim/6-week appointment giving 38/40
responses at this point (one was due to an administra-
tive error, the other due to patient availability) and
both of these participants were in group B. Informa-
tion for this is detailed in the included CONSORT
2010 flow diagram (figure 2).
There was mean age of the participants of 52.1 years;
33% were male. At entry into the study, the partici-
pants had a mean duration of symptoms of 25.2
months, and had a mean body mass index of 30.8 kg/
m2. There were no statistically significant differences in
any of the demographics recorded between partici-
pants in group A (intervention) and group B (control),
and these figures are displayed in table 1, with figures
displayed as mean (SD).
Patient-rated outcome measures
There were no differences in any of the baseline
PROMs studied between the members of the two
groups, except for the self-reported ‘worst pain’ which
did differ significantly at baseline (group A/interven-
tion=8.0/10, group B/control=9.0/10, p=0.032), and it
was not clear if this could have influenced subsequent
analysis.
The baseline and follow-up variables for both group
A and group B are displayed in table 2, figures shown
are mean (SD), significance was calculated between
group A and B at the same time point (column), and
between the follow-up period and the baseline for both
groups (row). (* indicates statistically significant
change, but specific p values are not displayed to aid
clarity). While improvements were seen in a number of
the measures studied in members in both groups,
including pain, and specific local foot function, there
was no statistically significant differences seen between
the two groups studied except for the sport subscore of
the FAAM questionnaire favouring the control group,
the significance of this was unclear.
Physical parameters
In group A (intervention group), there were statisti-
cally significant improvements in flexibility measured
with the knee-to-wall test at 6 weeks only, but not at
3months. In addition, significant changes were seen
in the popliteal angle at 3months, but not at
6weeks. There were no significant changes in flexi-
bility seen in group B at any of the time points
studied. However, when comparing the groups at
each time point, none of the physical parameters of
flexibility measured reached a statistical significant
difference between group A and group B at any of
the time points studied.
There were no significant differences in plantar
fascia thickness between members of group A and
group B and baseline or either of the follow-up periods
studied. In the members of group B only, the plantar
fascia thickness decreased to a statistical significant
amount between values recorded at baselines and those
at both the 6-week and 3-month time points; the clin-
ical significance of this is uncertain.
The figures for the physical parameters measured
are displayed in table 3, figures displayed are mean
(SD).
DISCUSSION
In keeping with previous published research, this study
has shown improvements in several domains of pain
and self-reported function in patients with the HEP
both with and without the TNS. It is important to note
that these benefits were seen in patients with very
chronic symptoms, with an average of 2 years, which is
far longer premorbid symptoms than many other
previously published works.59 It is not clear if this
duration of prior symptoms has had a direct effect on
the outcomes seen, as most patients with plantar fasci-
itis symptoms will improve within 6 to 12 months, and
there may be better results from earlier treatments,
although this remains unclear.1
Pain/PROMs results
Members of both groups had statistically significant
improvements in self-reported pain levels of pain of
approximately 1.5 points on a 0–10 pain scale at
3months, which exceeded the minimally important
differences of the equivalent of 0.9 points found in
previous research.60 However, there appeared to be
little, if any, significant difference between the two
groups seen at any time point suggesting minimal
additional benefit from the addition of a TNS device
to a structure HEP. The data were all analysed on
Table 1 Demographic information for subjects
Group A Intervention
group  
(n=20)
HEP+TNS
Group B Control
group  
(n=20)
HEP alone p Value
Age 53.4 (8.9) 50.9 (11.7) 0.444
Gender (%
male)
25% 35% 0.503
BMI (kg/m2) 32.6 (5.0) 29.0 (4.9) 0.071
Symptom
duration
(months)
30.3 (33.2) 20.1 (9.2) 0.204
BMI, body mass index; HEP, home exercise programme;
TNS, tension night splint.
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Table 2 Patient-rated outcome measures (PROMs) at baseline and follow-up
PROMs/group Baseline 6weeks 3months
‘Average pain’
(0–10)
A 6.8 (2.2) 5.6 (2.8)* 5.3 (2.6)*
B 7.1 (1.7) 6.2 (2.6) 5.6 (2.9)*
‘Pain at its worst’
(0–10)
A 8.0 (1.7) 6.6 (2.6)* 5.9 (2.9)*
B 9.0 (1.0)* 7.1 (2.6)* 6.7 (3.2)*
‘Pain at its best’
(0–10)
A 5.2 (2.4) 4.2 (2.5)* 3.7 (2.2)*
B 5.5 (2.4) 4.4 (3.0) 4.4 (3.0)
‘Pain in the morning’
(0–10)
A 7.3 (2.2) 5.8 (2.6)* 5.2 (2.7)*
B 8.3 (1.3) 6.8 (2.9)* 5.8 (3.4)*
‘Pain in the evening’
(0–10)
A 6.9 (2.1) 6.1 (2.9) 5.5 (2.8)*
B 7.7 (1.4) 5.9 (3.2)* 6.0 (3.1)*
‘Pain at rest’
(0–10)
A 5.4 (2.7) 4.3 (2.9)* 4.3 (2.4)*
B 6.0 (2.2) 5.2 (2.7) 4.9 (3.0)
‘Pain when walking’
(0–10)
A 7.1 (2.3) 5.7 (2.8)* 5.5 (2.8)*
B 7.5 (1.8) 5.6 (3.2)* 5.5 (3.1)*
‘Average stiffness’
(0–10)
A 6.0 (3.2) 4.9 (2.9) 4.3 (2.9)*
B 6.5 (3.0) 6.1 (2.6) 4.6 (3.2)*
‘Stiffness in the morning’
(0–10)
A 6.7 (3.0) 5.3 (2.9) 4.9 (3.0)
B 5.7 (3.2) 6.3 (3.2) 4.6 (3.6)
painDETECT
(0–38, lower score indicating lower likelihood of neuropathic pain)
A 13.4 (8.6) 11.4 (7.3) 11.9 (8.0)
B 15.4 (7.3) 13.6 (7.5) 11.9 (5.2)*
MOXFQ (total score)
(range 16–48, lower score=better function)
A 56.2 (14.5) 50.3 (16.0)* 49.2 (16.2)*
B 64.5 (12.0) 58.4 (16.7) 51.8 (17.2)*
FFI-R (total)
(range 34–136, with lower score indicating better function)
A 88.3 (24.5) 81.4 (24.0) 77.6 (25.4)*
B 95.5 (22.9) 86.6 (22.5) 77.0 (27.4)*
FAAM—%score
(higher score = better function)
A 56% (23%) 58% (23%) 67% (22%)*
B 55% (20%) 61% (19%)* 66% (23%)*
FAAM—%function
(higher score indicating better function)
A 56% (28%) 61% (25%) 53% (27%)
B 61% (13%) 65% (26%) 68% (22%)*
FAAM—%sport score
(higher score indicating better function)
A 36% (27%) 39% (29%) 44% (31%)
B 34% (22%) 43% (20%) 44% (31%)
FAAM—%sport function
(higher score indicating better function)
A 34% (32%) 31% (25%) 37% (27%)
B 51% (28%) 53% (30%)* 67% (28%)*
HAD—anxiety subscale
(range 0–21, with lower score indicating fewer symptoms)
A 6.5 (4.7) 6.1 (3.5) 5.5 (4.0)
B 7.2 (5.0) 8.1 (4.6) 6.7 (4.9)
HAD—depression subscale
(range 0–21, with lower score indicating fewer symptoms)
A 5.7 (4.6) 6.6 (5.1) 5.6 (4.6)
B 6.1 (4.7) 5.8 (4.2) 5.1 (4.7)
PSQI (total score)
(range 0–21, with lower score indicating fewer symptoms)
A 8.7 (5.3) 10.4 (5.1) 8.8 (4.7)
B 10.1 (4.9) 10.7 (5.3) 10.2 (4.7)
Figures are mean(SD).
*Indicates statistically significant change from baseline for variable in row, or difference between group A and B for variable in column
(p values not displayed for clarity).
FAAM, Foot and Ankle Ability Measure; FFI-R Revised Foot Function Index; HAD, Hospital Anxiety and Depression; MOXFQ, Manchester-
Oxford Foot Questionnaire; PSQI, Pittsburgh Sleep Quality Index.
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an intention-to-treat basis, which could have reduced
any effects of the TNS, but this better represents the
effects seen in the real world with some patients
having limited compliance to the use of the device
for a variety of factors including comfort. In addi-
tion, it is noted that the majority of participants
were ‘helped’ rather than ‘cured’ within both groups,
and realistic advice needs to be given to patients
about expectations from treatment for those with
chronic symptoms.
There was a statistically significant improvement in
the intervention group of self-reported ‘average
pain’ from baseline to 6weeks of 1.2 points, and 1.5
points at 3months, which is compared with the self-
reported ‘morning pain’ improvements of 1.5 and
2.1 points, respectively, for self-reported pain first
things in the morning. This indicates that pain is
improved throughout the day with the HEP and
TNS, although the lack of differences between
groups suggests that the benefits seen may not be
attributed to the TNS device.
The control group also achieved significant
improvements in a range of pain measures including
self-reported average pain, worst pain, pain in the
morning, pain in the evening and pain when
walking. This was despite them only having the
same interventions within the study as they had
before entry and the reasons for this remain
unclear. It is possible that benefits were gained as
patients had better compliance with the exercise
programme within the study (the so-called
Hawthorne effect’; however, this cannot be reliably
determined from these data. Alternatively, it is
possible that these benefits were a simply as a conse-
quence of the natural resolution of the condition,
but as the average duration of symptoms in the
subjects in this group was in excess of 18 months, it
is not clear whether the benefits seen over a further
3-month period could be solely attributable to this,
and the mechanisms of benefits seen are unclear.
Improvements in foot function were seen in both
members of the intervention and control group, with
improvements in the MOXFQ score reaching statis-
tical significance in the intervention group at both
6weeks and 3months, but only at 3months in the
control group. This effect was reversed for the
FAAM questionnaire score which showed statistical
significant improvements in the intervention group
at 3months, but at the 6-week and 3-month point
for the control group. The FFI-R score changed to a
statistically significant amount in both groups at the
3-month time point, although it did not differ signif-
icantly between the groups, and the magnitude of
the improvements seen is greater than the seven
points found to be the minimum clinically significant
change in previous work.60 Overall, regarding
specific foot function PROMs, while some benefits
were seen, interpretation of any benefit being attrib-
uted to the TNS is unclear.
Although improvements in pain were seen in both
groups, there was no significant improvement in
mental health functioning for either anxiety or depres-
sive symptoms as assessed by the HAD questionnaire.
Somewhat reassuringly, although anecdotally patients
may report impaired sleep quality from the use of the
TNS devices, there was no statistically significant wors-
ening of sleep quality as assessed by the PSQI, in
members of the intervention group at either of the
follow-up time periods studied.
Physical parameters
Despite the improvements in pain seen, less definite
benefits were seen in either group across the
domains of physical flexibility. Improvements were
Table 3 Physical measurements at baseline and at follow-up
Physical parameters/group Baseline 6weeks 3months
Knee-to-wall distance (mm) A 89.0 (36.5) 100.3 (33.2)* 93.4 (37.0)
B 86.8 (41.5) 89.4 (35.9) 97.3 (39.1)
Ankle dorsiflexion angle—with knee straight A 93.7! (5.5!) 94.5 (5.0!) 95.1 (5.9!)
B 94.4! (5.5!) 96.8 (4.5!) 94.9 (5.8!)
Ankle dorsiflexion angle—with knee bent A 99.2! (7.0!) 101.2 (6.4!) 99.5 (5.3!)
B 98.6! (5.1!) 100.7 (5.7!) 99.8 (5.5!)
Popliteal angle A 145.9! (10.3!) 145.7 (21.1!) 150.8 (11.0!)*
B 145.8! (10.7!) 150.2 (9.7!) 147.8 (12.7!)
Plantar fascia thickness (mm) A 6.1 (1.4) 5.7 (1.5) 6.0 (1.9)
B 6.3 (1.2) 5.8 (1.1)* 5.7 (1.2)*
*Indicates significant change from baseline for variable in row.
Figures shown are mean (SD).
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found in two measures in the intervention group,
but no significant differences were seen between
different groups, and neither group showing consis-
tent improvements in flexibility. This differs from
previous work showing a close correlation between
the two variables.13
The plantar fascia thickness improved to a statisti-
cally significant extent in the control group, but not
the intervention group. The reasons for this, and any
clinical significance for the changes seen, remain
unclear, with previous published works showing a
correlation between reduction in plantar fascia thick-
ening and improvements in pain which was not seen
specifically in this study.58
Comparisons
The two groups were believed to be similar across a
range of measurements at baseline, and while patients
in the intervention group were slightly older, slightly
more overweight and with a longer duration of symp-
toms, none of these variables reached statistical
significance. Of the pain/function variables, the partici-
pants in the control group did have a statistically
higher self-reported ‘worst pain’ at baseline, although
the other variables were the same as the intervention
group, and it is not clear if this could have had an
influence on outcome results.
While improvements were seen in pain and local
function in both groups at 3months, the intervention
group who received the HEP and the TNS device
could possibly be considered to have improved quicker
with statistically significant improvements in a range of
outcome measures of pain at 6 weeks, whereas the
control group, who received the HEP only, tended to
require the full 3months before improvements were
more often seen. However, the significance of these
changes and benefits from the tension night splint
remain limited.
Possible limitations, and considerations for the future
Although both groups had improvements seen across
several of the outcome measures studied, there were
limited statistical differences seen between the groups.
A larger study population may be better able to
explore this and this could be the focus of further
study. In addition, this was a single-blinded study, in
which the participants but not the examiner knew
which group they had been allocated to. This was
chosen for pragmatic purposes, but could have had an
influence on the outcome. Further work could be done
with sham devices should funding be available to study
this as an intervention. Furthermore, this study only
used a single commercially available device, and it is
not clear if other commercially available devices or
custom-made devices have similar outcomes, and if any
differences exists between them, and this could be the
area of further investigation. Interobserver error is
recognised as a limitation for both the goniometer and
ultrasound measures, which was avoided with a single
investigator taking all of the measurements. Intraob-
server error was minimised with familiarity with the
techniques used, but could not be eliminated
completely and remains a recognised limitation of this
study.
Improvements in pain occurred in both groups
without necessarily seeing statistically significant
differences seen in measures of physical flexibility.
This may be that the study was underpowered to
detect small changes in flexibility reliably, and either
larger groups or more robust methods are needed.
Alternatively, it may be that the improvements seen
represent changes other than that directly from
changes in flexibility, such as improvements in the
load tolerability of tissue, or desensitisation of tissue,
and exploring these areas could be the focus of
further work.
Summary
Overall this study has shown that even in patients with
very chronic symptoms of an average of 2 years,
improvements in pain and function can be found using
a structured HEP. However, from the data seen here, it
appears that the addition of a TNS does not have
much, if any, benefit beyond this in the treatment of
this population.
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